Efficacy of venetoclax plus anti-CD38 monoclonal antibody-containing therapies among t(11;14) positive multiple myeloma patients regardless of timing of prior treatment with this antibody

被引：2
|
作者：
Regidor, Bernard Sean [1 ]
Siddiqi, Dilawer [1 ]
Beatty, Bethany Marie [1 ]
Goldwater, Marissa-Skye [2 ]
Jew, Scott [1 ,2 ]
Bujarski, Sean [1 ,2 ]
Swift, Regina [1 ]
Kim, Susanna
Berenson, James R. R. [1 ,2 ,3 ,4 ]
机构：
[1] Berenson Canc Ctr, West Hollywood, CA USA
[2] Inst Myeloma & Bone Canc Res, West Hollywood, CA USA
[3] Oncotherapeut, West Hollywood, CA USA
[4] Inst Myeloma & Bone Canc Res, 9201 W Sunset Blvd,Ste 300, West Hollywood, CA 90069 USA
来源：
EUROPEAN JOURNAL OF HAEMATOLOGY | 2023年 / 110卷 / 02期
关键词：
anti-CD38; daratumumab; multiple myeloma; venetoclax;
D O I：
10.1111/ejh.13896
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：222 / 223
页数：2
相关论文
共 37 条
  • [21] SG301, a Novel Anti-CD38 Monoclonal Antibody, in Patients with Relapsed/Refractory Multiple Myeloma: A First-in-Human, Multicentre, Phase 1 Trial
    Tian, Ying
    Zhou, Keshu
    Lin, Quande
    Qian, Wenbin
    Yang, Wei
    Sao, Li
    Yuan, Guolin
    Yan, Xiaojing
    Ma, Liangming
    Zhou, Xin
    Liu, Lihong
    Zhu, Fangbing
    Zuo, Xuelan
    Du, Xin
    Ji, Xu
    Zhang, Xuzhao
    Shen, Jing
    Zhou, Hai
    Li, Na
    Chen, Wenming
    BLOOD, 2024, 144 : 4746 - 4747
  • [22] HORIZON (OP-106): Melflufen Plus Dexamethasone in Relapsed/ Refractory Multiple Myeloma (RRMM) Refractory to Pomalidomide and/or an Anti-CD38 Monoclonal Antibody (mAb) - Final Primary Analysis
    不详
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S295 - S296
  • [23] HORIZON (OP-106): Melflufen Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to Pomalidomide and/or an Anti-CD38 Monoclonal Antibody (mAb) - Final Primary Analysis
    Richardson, Paul G.
    Oriol, Albert
    Larocca, Alessandra
    Blade, Joan
    Cavo, Michele
    Rodriguez-Otero, Paula
    Leleu, Xavier
    Norkin, Maxim
    Nadeem, Omar
    Hiemenz, John W.
    Hassoun, Hani
    Touzeau, Cyrille
    Alegre, Adrian
    Paner, Agne
    Maisel, Christopher
    Mazumder, Amitabha
    Raptis, Anastasios
    Puig, Noemi
    Harmenberg, Johan
    Byrne, Catriona
    Thuresson, Sara
    Obermueller, Jakob
    Mateos, Maria-Victoria
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S295 - S295
  • [24] A phase Ib study of TAK-079, an investigational anti-CD38 monoclonal antibody (mAb) in patients with relapsed/ refractory multiple myeloma (RRMM): Preliminary results.
    Krishnan, Amrita Y.
    Patel, Krina K.
    Hari, Parameswaran
    Jagannath, Sundar
    Niesvizky, Ruben
    Silbermann, Rebecca Wang
    Berg, Deborah T.
    Li, Qing
    Allikmets, Kristina
    Stockerl-Goldstein, Keith
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [25] Cumulative Incidence and Relative Risk of Infection in Patients With Multiple Myeloma Treated With Anti-CD38 Monoclonal Antibody-Based Regimens: A Systematic Review and Meta-analysis
    Vassilopoulos, Stephanos
    Vassilopoulos, Athanasios
    Kalligeros, Markos
    Shehadeh, Fadi
    Mylonakis, Eleftherios
    OPEN FORUM INFECTIOUS DISEASES, 2022, 9 (11):
  • [26] HORIZON (OP-106) Versus MAMMOTH: An Indirect Comparison of Efficacy Outcomes for Patients with Relapsed/Refractory Multiple Myeloma Refractory (RRMM) to Anti-CD38 Monoclonal Antibody Therapy Treated with Melflufen Plus Dexamethasone Versus Conventional Agents
    Creixenti, Joan Blade
    Mateos, Maria-Victoria
    Oriol, Albert
    Larocca, Alessandra
    Cavo, Michele
    Rodriguez-Otero, Paula
    Leleu, Xavier
    Norkin, Maxim
    Nadeem, Omar
    Hiemenz, John W.
    Hassoun, Hani
    Touzeau, Cyrille
    Amor, Adrian Alegre
    Paner, Agne
    Maisel, Christopher
    Mazumder, Amitabha
    Raptis, Anastasios
    Puig, Noemi
    Zavisic, Stojan
    Thuresson, Marcus
    Harmenberg, Johan
    Richardson, Paul G.
    BLOOD, 2020, 136
  • [27] Post-Vaccination Anti-SARS-CoV-2-Antibody Response in Patients with Multiple Myeloma Correlates with Low CD19+B-Lymphocyte Count and Anti-CD38 Treatment
    Ghandili, Susanne
    Schonlein, Martin
    Lutgehetmann, Marc
    zur Wiesch, Julian Schulze
    Becher, Heiko
    Bokemeyer, Carsten
    Sinn, Marianne
    Weisel, Katja C.
    Leypoldt, Lisa B.
    CANCERS, 2021, 13 (15)
  • [28] Poor post-vaccination anti-SARS-CoV-2-antibody response in patients with Multiple Myeloma correlates with low CD19+B-lymphocyte count and anti-CD38 treatment
    Ghandili, Susanne
    Schonlein, Martin
    Lutgehetmann, Marc
    Wiesch, Julian Schulze Zur
    Becher, Heiko
    Bokemeyer, Carsten
    Sinn, Marianne
    Weisel, Katja
    Leypoldt, Lisa
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S31 - S32
  • [29] Y MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial
    Raab, Marc S.
    Engelhardt, Monika
    Blank, Antje
    Goldschmidt, Hartmut
    Agis, Hermine
    Blau, Igor W.
    Einsele, Hermann
    Ferstl, Barbara
    Schub, Natalie
    Roellig, Christoph
    Weisel, Katja
    Winderlich, Mark
    Griese, Janine
    Haertle, Stefan
    Weirather, Johannes
    Jarutat, Tiantom
    Peschel, Christian
    Chatterjee, Manik
    LANCET HAEMATOLOGY, 2020, 7 (05): : E381 - E394
  • [30] Preliminary Results from a Phase 1b Study of TAK-079, an Investigational Anti-CD38 Monoclonal Antibody (mAb) in Patients with Relapsed/ Refractory Multiple Myeloma (RRMM)
    Krishnan, Amrita Y.
    Patel, Krina K.
    Hari, Parameswaran
    Jagannath, Sundar
    Niesvizky, Ruben
    Silbermann, Rebecca W.
    Berg, Deborah
    Lin, Jianchang
    Fedyk, Eric Robert
    Palumbo, Antonio
    Stockerl-Goldstein, Keith E.
    BLOOD, 2019, 134
1234